Evidence map›Paper›PMID 41013395›Full record

ArticleBMC nephrology2025

Effects of sodium zirconium cyclosilicate on the quality of life of patients with hyperkalemia undergoing hemodialysis: Y-QOL study design.

Shiori Yoshimura, Daisuke Kanai, Hiromichi Wakui, Rika Furuta, Shunichi Fukuhara, Sayaka Shimizu, Kouji Yamamoto, Yusuke Saigusa, Masaaki Hanaoka, Hiroshi Mitsuhashi and 18 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Shiori Yoshimura *Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Daisuke Kanai *Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Hiromichi Wakui *Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan. hiro1234@yokohama-cu.ac.jp.
Rika FurutaDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Shunichi FukuharaSection of Clinical Epidemiology, Department of Community Medicine, Graduate School of Medicine, Kyoto University, Shogoin Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.
Sayaka ShimizuSection of Clinical Epidemiology, Department of Community Medicine, Graduate School of Medicine, Kyoto University, Shogoin Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.
Kouji YamamotoDepartment of Biostatistics, School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Kanagawa, 236-0004, Japan.
Yusuke SaigusaDepartment of Biostatistics, School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Kanagawa, 236-0004, Japan.
Masaaki HanaokaKohsaikai Kamioooka Jinsei Clinic, 1-10-1 Kamioooka Nishi, Konan-ku, Yokohama, 233-0002, Kanagawa, Japan.
Hiroshi MitsuhashiKohsaikai Kamioooka Jinsei Clinic, 1-10-1 Kamioooka Nishi, Konan-ku, Yokohama, 233-0002, Kanagawa, Japan.
Tomoyuki KawanoKohsaikai Bunko Jin Clinic, 356-3 Yatsucho, Kanazawa-ku, Yokohama, Kanagawa, 236-0016, Japan.
Mari KatsumataKohsaikai Kanazawa Clinic, 19-9 Seto, Kanazawa-ku, Yokohama, Kanagawa, 236-0027, Japan.
Satoshi YamaguchiKohsaikai Kanazawa Clinic, 19-9 Seto, Kanazawa-ku, Yokohama, Kanagawa, 236-0027, Japan.
Nariaki OgawaKohsaikai Oppama Jinsei Clinic, 3-1 Oppamacho, Yokosuka, Kanagawa, 237-0064, Japan.
Masato OhsawaYokodai Central Clinic, 3-9-31 Yokodai, Isogo-ku, Yokohama, Kanagawa, 235-0045, Japan.
Kohji OhkiYokodai Central Clinic, 3-9-31 Yokodai, Isogo-ku, Yokohama, Kanagawa, 235-0045, Japan.
Masahiro NishiharaYokohama Minami Clinic, 3-3-1 Konandai, Konan-ku, Yokohama, Kanagawa, 234-0054, Japan.
Sho KinguchiDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Kengo AzushimaDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Tomohiko KanaokaDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Yusuke KobayashiDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Yoshiyuki ToyaKohsaikai Kamioooka Jinsei Clinic, 1-10-1 Kamioooka Nishi, Konan-ku, Yokohama, 233-0002, Kanagawa, Japan.
Takeo IshiiDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Ashio YoshimuraYokohama Daiichi Hospital Zenjinkai, 2-5-15 Takashima, Nishi-ku, Yokohama, Kanagawa, 220-0011, Japan.
Gen YasudaYokohama Higashiguchi Jin Clinic Zenjinkai, 2-5-18 Takashima, Nishi-ku, Yokohama, Kanagawa, 220-0011, Japan.
Tadashi KujiYokohama Minami Clinic, 3-3-1 Konandai, Konan-ku, Yokohama, Kanagawa, 234-0054, Japan.
Toshimasa OhnishiKohsaikai Kamioooka Jinsei Clinic, 1-10-1 Kamioooka Nishi, Konan-ku, Yokohama, 233-0002, Kanagawa, Japan.
Kouichi TamuraDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients undergoing hemodialysis (HD) face severe dietary potassium restrictions, reducing their quality of life (QOL) and potentially worsening their prognosis. Sodium zirconium cyclosilicate (SZC) is a novel selective potassium binder that lowers potassium levels, with minimal effects on other electrolytes. The Y-QOL study will evaluate whether SZC can improve QOL by easing the burden of dietary restrictions. This 8-week, multicenter, randomized, parallel-group, open-label trial will enroll 200 outpatients with hyperkalemia (potassium level 5.5-6.4 mEq/L after a 2-day inter-dialytic interval) on thrice-weekly HD. Participants will be randomized to receive SZC (starting dose 5 g on non-dialysis days, adjustable to 15 g based on serum potassium levels) plus dietary guidance, or dietary guidance alone to maintain serum potassium levels at 4.0-5.4 mEq/L. The primary endpoint is changes in The 7-item QOL Disease-specific Impact Scale (QDIS-7) scores at week 8 from baseline. Secondary endpoints include additional QOL scores, nutritional status, inflammation markers, Bristol Stool Form Scale, serum potassium reduction, and safety. Recruitment began on January 24, 2024, and the study will conclude on March 31, 2026. The Y-QOL study aims to determine the effectiveness of SZC in improving QOL by reducing serum potassium levels in patients with hyperkalemia undergoing HD.

Indexed as

HyperkalemiaQuality of LifeRenal DialysisSilicatesAgedFemaleHumansMaleMiddle AgedMulticenter Studies as TopicPotassiumRandomized Controlled Trials as TopicPotassiumSilicatessodium zirconium cyclosilicateHemodialysisHyperkalemiaNutritionQuality of lifeSodium zirconium cyclosilicate

Identifiers

PMID41013395
PMCPMC12465238

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.